About a quarter of participants (26.9%) were using SGLT2 inhibitors at baseline, and 48.9% used an SGLT2 inhibitor during SOUL
The medication works by mimicking the action of the naturally occurring hormone GLP-1, which stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon release, slows gastric emptying, and reduces appetite through effects on the central nervous system
Yet, the role of GLP-1RAs in modulating energy balance and growth during juvenile malnutrition, a period marked by significant disruptions in these processes, remain largely unexplored
A new lower dose Notably, Lilly also tested a lower 4-milligram dose not used in other trials, and it helped patients lose 19% of their weight, or 47.2 pounds, over 80 weeks
Administration guide for each dose Knowing how many units to draw is only half the equation